$125 million rev is a terrific result for 2022. The level of recurring revenues will be interesting when the full Sep year results are announced in Nov. The ability to get global sales in G2 will make GTK an attractive takeover candidate…..hopefully not too soon
- Forums
- ASX - By Stock
- Ann: Gentrack provides updated guidance for FY22
$125 million rev is a terrific result for 2022. The level of...
Featured News
Add GTK (ASX) to my watchlist
|
|||||
Last
$9.63 |
Change
0.010(0.10%) |
Mkt cap ! $996.6M |
Open | High | Low | Value | Volume |
$9.63 | $9.68 | $9.55 | $485.8K | 50.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 220 | $9.59 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$9.66 | 220 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 220 | 9.590 |
1 | 220 | 9.580 |
1 | 220 | 9.570 |
1 | 220 | 9.560 |
1 | 941 | 9.550 |
Price($) | Vol. | No. |
---|---|---|
9.660 | 220 | 1 |
9.670 | 220 | 1 |
9.680 | 220 | 1 |
9.690 | 220 | 1 |
9.740 | 127 | 1 |
Last trade - 16.10pm 24/07/2024 (20 minute delay) ? |
Featured News
GTK (ASX) Chart |
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, CEO
Paul Long
CEO
Previous Video
Next Video
SPONSORED BY The Market Online